{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:22:04Z","timestamp":1771935724767,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Peritoneal recurrence is the most common form of recurrence after radical gastrectomy for gastric cancer (GC) and is the main cause of death. The median survival period is 3\u20136 months, and the 5-year survival rate is almost zero. So far, the treatment methods recommended by various clinical guidelines for peritoneal metastasis (PM) of GC are all palliative systemic chemotherapy (SC). However, the therapeutic effect is not ideal. One possible reason is the existence of the blood-peritoneal barrier, which makes it difficult for drugs to reach the peritoneal metastatic foci fully. Based on this, surgeons have gradually attempted the intraperitoneal administration mode in clinical practice. Hyperthermic intraperitoneal chemotherapy (HIPEC) improves the anti-tumor efficacy through the synergistic effect of heat and chemotherapy drugs and has achieved good therapeutic effects in the treatment of PM of GC. Raltitrexed is mainly used for intravenous administration and intraperitoneal chemotherapy for advanced colorectal cancer. HIPEC with raltitrexed for the treatment of PM after radical gastrectomy for GC is extremely rare. This article introduces a case of advanced GC with peritoneal recurrence and a large amount of ascites 11 months after radical gastrectomy. After 5 cycles of HIPEC with raltitrexed, a favorable therapeutic effect was achieved. The patient experienced significant clinical improvement, characterized by the resolution of ascites, alleviation of symptoms, and prolonged survival, thereby creating an opportunity for subsequent comprehensive treatment. It is hoped that this case can provide a treatment option for patients with peritoneal recurrence after radical gastrectomy for GC.<\/jats:p>","DOI":"10.3389\/fonc.2026.1701376","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:18:35Z","timestamp":1771305515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperthermic intraperitoneal chemotherapy with raltitrexed for peritoneal recurrence presenting with massive ascites following radical surgery for advanced gastric cancer: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenjie","family":"Xie","sequence":"first","affiliation":[{"name":"Department of General Surgery, The Third Hospital of Mianyang, Sichuan Mental Health Center","place":["Mianyang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of pediatrics, The Third Hospital of Mianyang, Sichuan Mental Health Center","place":["Mianyang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongkun","family":"Mou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Third Hospital of Mianyang, Sichuan Mental Health Center","place":["Mianyang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Third Hospital of Mianyang, Sichuan Mental Health Center","place":["Mianyang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet (London England)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101685","article-title":"Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer-A systematic review","volume":"8","author":"Brenkman","year":"2019","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e11949","DOI":"10.1097\/MD.0000000000011949","article-title":"Comparative effectiveness of hyperthermic intraperitoneal chemotherapy for gastric cancer: A systematic review and network meta-analysis protocol","volume":"97","author":"Cai","year":"2018","journal-title":"Medicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.03.016","article-title":"A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent","volume":"42","author":"Yonemura","year":"2016","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041125","article-title":"10 years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): A systematic review and meta-analysis","volume":"15","author":"Di Giorgio","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12312-7","article-title":"Impact of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis: A systematic review and meta-analysis","volume":"29","author":"Martins","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","article-title":"Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials","volume":"40","author":"Coccolini","year":"2014","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519882545","article-title":"Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials","volume":"47","author":"Liu","year":"2019","journal-title":"J Int Med Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-2197.2006.03579.x","article-title":"Review of patients with peritoneal Malignancy treated with peritonectomy and heated intraperitoneal chemotherapy","volume":"76","author":"Hadi","year":"2006","journal-title":"ANZ J Surg"},{"key":"B14","article-title":"Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome","volume":"27","author":"Pohlen","year":"2007","journal-title":"Anticancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1407","article-title":"Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma","volume":"7","author":"Poon","year":"1989","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"Lancet (London England)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/1477-7819-12-403","article-title":"Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer","volume":"12","author":"Zhao","year":"2014","journal-title":"World J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1186\/s12885-024-12831-4","article-title":"Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study","volume":"24","author":"Cheng","year":"2024","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58481","article-title":"A clinical study of intraoperative perfusion chemotherapy with raltitrexed in colon cancer: A prospective cohort study","volume":"16","author":"Adnan","year":"2024","journal-title":"Cureus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8857","DOI":"10.1038\/s41467-024-52700-z","article-title":"Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1186\/s12885-025-14274-x","article-title":"RALOX-HAIC (raltitrexed\u2009+\u2009oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma","volume":"25","author":"Lu","year":"2025","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1701376\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:28:46Z","timestamp":1771932526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1701376\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1701376"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1701376","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"1701376"}}